摘要
目的:胶质瘤是人类中枢神经系统中最常见的恶性肿瘤,胶质瘤病人预后差、生存期短,寻找新的诊疗靶点以提高胶质瘤早期诊治率,改善胶质瘤患者预后,延长生存期,是目前临床亟待解决的问题。方法:在本研究中,我们从胶质瘤基因组图谱数据库中下载LncRNAs表达谱,通过R语言基因芯片分析技术筛选出胶质瘤中差异表达的LncRNA,通过LncRNA芯片(Agilent-045997 Arraystar human LncRNA microarray V3)对5例正常脑组织及5例胶质瘤组织中LncRNA的差异表达情况进行检测,选取差异表达最显著的LncRNA。随后,我们利用逆转录定量聚合酶链反应(RT-PCR)技术对63例患者差异基因的表达情况进行检测,分析其与胶质瘤临床病理特征及预后的关系。结果:通过聚类分析,我们发现LncRNA-TSIX是胶质瘤中表达差异最显著的LncRNA。RT-PCR结果发现胶质瘤中LncRNA-TSIX的表达量较正常组织显著下调,且在不同级别胶质瘤组织中表达量逐级下调,差异具有统计学意义(P < 0.01)。临床特征相关性分析显示LncRNA-TSIX与胶质瘤的恶性程度(WHO分级)密切相关。生存分析显示LncRNA-TSIX的低表达或表达缺失的患者预后更差。结论:胶质瘤组织中LncRNA-TSIX的表达与胶质瘤的进展及预后密切相关,有望成为协助胶质瘤诊断、治疗和预后方面的关键分子。
Objective: Glioma is the most common malignant tumor in the human central nervous system. Glioma patients have poor prognosis and short survival. Searching for new diagnostic and therapeutic targets to improve the early diagnosis and treatment rate of glioma, improve the prognosis of glioma patients, and extend their survival time is an urgent clinical problem to be solved. Methods: In this study, we downloaded the expression profiles of LncRNAs from the glioma genome atlas database. Differentially expressed LncRNAs in glioma were screened using R language gene chip analysis technology. An LncRNA microarray (Agilent-045997 Arraystar human LncRNA microarray V3) was used to detect the differential expression of LncRNAs in 5 normal brain tissues and 5 glioma tissues, and the most significantly differentially expressed LncRNA was selected. Subsequently, we used reverse transcription quantitative polymerase chain reaction (RT-PCR) technology to detect the expression of the differentially expressed gene in 63 patients and analyze its relationship with the clinicopathological characteristics and prognosis of glioma. Results: Through cluster analysis, we found that LncRNA-TSIX was the most significantly differentially expressed LncRNA in glioma. RT-PCR results showed that the expression of LncRNA-TSIX in glioma was significantly downregulated compared with normal tissues, and its expression gradually decreased in different grades of glioma tissues, with statistically significant differences (P < 0.01). Clinical feature correlation analysis showed that LncRNA-TSIX was closely related to the malignancy of glioma (WHO grade). Survival analysis showed that patients with low expression or absence of LncRNA-TSIX had worse prognosis. Conclusion: The expression of LncRNA-TSIX in glioma tissues is closely related to the progression and prognosis of glioma, and is expected to become a key molecule in assisting the diagnosis, treatment, and prognosis of glioma.
出处
《临床医学进展》
2024年第5期1953-1961,共9页
Advances in Clinical Medicine
